Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Decreases By 56.7%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 191,156 shares, a decrease of 56.7% from the February 12th total of 441,371 shares. Approximately 9.6% of the company’s shares are sold short. Based on an average daily trading volume, of 435,180 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 435,180 shares, the short-interest ratio is currently 0.4 days. Approximately 9.6% of the company’s shares are sold short.

Moleculin Biotech Stock Down 0.5%

Shares of NASDAQ MBRX traded down $0.01 during trading on Thursday, reaching $2.02. 99,455 shares of the stock were exchanged, compared to its average volume of 189,314. The company has a market capitalization of $4.12 million, a price-to-earnings ratio of -0.06 and a beta of 1.73. The business’s 50-day moving average price is $3.66 and its 200 day moving average price is $7.53. Moleculin Biotech has a twelve month low of $1.79 and a twelve month high of $33.00.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MBRX shares. Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective (up from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Moleculin Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $61.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.